LAMICTAL XR
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Jan 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
LAMICTAL XR by GSK is mechanism(s) by which lamotrigine exerts its anticonvulsant action are unknown. First approved in 2010.
Drug data last refreshed 17h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LAMICTAL XR is an extended-release oral tablet formulation of lamotrigine, a small-molecule anticonvulsant approved in 2010. The precise mechanism of action remains unknown, though it likely involves inhibition of voltage-sensitive sodium channels and modulation of excitatory neurotransmitter release. It is indicated for epilepsy and other neurological conditions where seizure prevention is therapeutically important.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential team restructuring and transition focus toward next-generation pipeline assets.
Mechanism of Action
mechanism(s) by which lamotrigine exerts its anticonvulsant action are unknown. In animal models designed to detect anticonvulsant activity, lamotrigine was effective in preventing seizure spread in the maximum electroshock (MES) and pentylenetetrazol (scMet) tests, and prevented seizures in the…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on LAMICTAL XR at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.